MA61557B1 - Composés et compositions servant d'inhibiteurs de sppl2a - Google Patents
Composés et compositions servant d'inhibiteurs de sppl2aInfo
- Publication number
- MA61557B1 MA61557B1 MA61557A MA61557A MA61557B1 MA 61557 B1 MA61557 B1 MA 61557B1 MA 61557 A MA61557 A MA 61557A MA 61557 A MA61557 A MA 61557A MA 61557 B1 MA61557 B1 MA 61557B1
- Authority
- MA
- Morocco
- Prior art keywords
- inhibitors
- sppl2a
- compositions
- compounds
- peptidase
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063079604P | 2020-09-17 | 2020-09-17 | |
| EP21773886.3A EP4214210B1 (en) | 2020-09-17 | 2021-09-15 | Compounds and compositions as sppl2a inhibitors |
| PCT/IB2021/058398 WO2022058902A1 (en) | 2020-09-17 | 2021-09-15 | Compounds and compositions as sppl2a inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA61557B1 true MA61557B1 (fr) | 2025-05-30 |
Family
ID=77897680
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA61557A MA61557B1 (fr) | 2020-09-17 | 2021-09-15 | Composés et compositions servant d'inhibiteurs de sppl2a |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US20230365571A1 (https=) |
| EP (2) | EP4578451A3 (https=) |
| JP (2) | JP7771172B2 (https=) |
| KR (1) | KR20230069947A (https=) |
| AU (1) | AU2021342783A1 (https=) |
| CA (1) | CA3192763A1 (https=) |
| CL (2) | CL2023000728A1 (https=) |
| CO (1) | CO2023004646A2 (https=) |
| CR (1) | CR20230142A (https=) |
| DK (1) | DK4214210T3 (https=) |
| DO (1) | DOP2023000055A (https=) |
| EC (1) | ECSP23027092A (https=) |
| ES (1) | ES3028668T3 (https=) |
| FI (1) | FI4214210T3 (https=) |
| GE (2) | GEAP202516217A (https=) |
| HR (1) | HRP20250562T1 (https=) |
| HU (1) | HUE071569T2 (https=) |
| IL (1) | IL300953B1 (https=) |
| JO (1) | JOP20230044A1 (https=) |
| LT (1) | LT4214210T (https=) |
| MA (1) | MA61557B1 (https=) |
| MD (1) | MD4214210T2 (https=) |
| MX (1) | MX2023003122A (https=) |
| PE (1) | PE20231099A1 (https=) |
| PL (1) | PL4214210T3 (https=) |
| PT (1) | PT4214210T (https=) |
| RS (1) | RS66874B1 (https=) |
| SI (1) | SI4214210T1 (https=) |
| SM (1) | SMT202500216T1 (https=) |
| WO (1) | WO2022058902A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116947813A (zh) * | 2023-07-06 | 2023-10-27 | 绍兴贝斯美化工股份有限公司 | 一种3-氯-4-氨基-1-(3-吡啶基)-1h-吡唑的制备方法 |
| US20250263416A1 (en) | 2024-02-15 | 2025-08-21 | Incyte Corporation | SPPL2a INHIBITORS |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2124503C1 (ru) * | 1992-05-18 | 1999-01-10 | И.Р.Сквибб энд Санз, Инк. | Гетероциклические азотсодержащие производные карбоновой кислоты, способ их получения и фармацевтическая композиция |
| GB9612622D0 (en) | 1996-06-17 | 1996-08-21 | Zeneca Ltd | Chemical process |
| US6432944B1 (en) | 2000-07-06 | 2002-08-13 | Bristol-Myers Squibb Company | Benzodiazepinone β-amyloid inhibitors: arylacetamidoalanyl derivatives |
| WO2004078163A2 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| EP1773348A4 (en) | 2004-07-12 | 2009-05-20 | Idun Pharmaceuticals Inc | TETRA PEPTIDE ANALOGS |
| JP2008545780A (ja) | 2005-06-08 | 2008-12-18 | ノバルティス アクチエンゲゼルシャフト | 有機化合物 |
| WO2015160772A1 (en) | 2014-04-15 | 2015-10-22 | Janssen Pharmaceutica Nv | Tetrahydro-benzoimidazolyl modulators of tgr5 |
-
2021
- 2021-09-15 MX MX2023003122A patent/MX2023003122A/es unknown
- 2021-09-15 ES ES21773886T patent/ES3028668T3/es active Active
- 2021-09-15 LT LTEPPCT/IB2021/058398T patent/LT4214210T/lt unknown
- 2021-09-15 GE GEAP202516217A patent/GEAP202516217A/en unknown
- 2021-09-15 PL PL21773886.3T patent/PL4214210T3/pl unknown
- 2021-09-15 CR CR20230142A patent/CR20230142A/es unknown
- 2021-09-15 MA MA61557A patent/MA61557B1/fr unknown
- 2021-09-15 HU HUE21773886A patent/HUE071569T2/hu unknown
- 2021-09-15 PT PT217738863T patent/PT4214210T/pt unknown
- 2021-09-15 RS RS20250568A patent/RS66874B1/sr unknown
- 2021-09-15 GE GEAP202116217A patent/GEP20257771B/en unknown
- 2021-09-15 US US18/044,455 patent/US20230365571A1/en active Pending
- 2021-09-15 KR KR1020237011546A patent/KR20230069947A/ko active Pending
- 2021-09-15 PE PE2023001167A patent/PE20231099A1/es unknown
- 2021-09-15 MD MDE20230725T patent/MD4214210T2/ro unknown
- 2021-09-15 FI FIEP21773886.3T patent/FI4214210T3/fi active
- 2021-09-15 EP EP25163259.2A patent/EP4578451A3/en active Pending
- 2021-09-15 JP JP2023517751A patent/JP7771172B2/ja active Active
- 2021-09-15 AU AU2021342783A patent/AU2021342783A1/en active Pending
- 2021-09-15 HR HRP20250562TT patent/HRP20250562T1/hr unknown
- 2021-09-15 IL IL300953A patent/IL300953B1/en unknown
- 2021-09-15 EP EP21773886.3A patent/EP4214210B1/en active Active
- 2021-09-15 SI SI202130298T patent/SI4214210T1/sl unknown
- 2021-09-15 DK DK21773886.3T patent/DK4214210T3/da active
- 2021-09-15 SM SM20250216T patent/SMT202500216T1/it unknown
- 2021-09-15 WO PCT/IB2021/058398 patent/WO2022058902A1/en not_active Ceased
- 2021-09-15 CA CA3192763A patent/CA3192763A1/en active Pending
-
2023
- 2023-02-27 JO JOJO/P/2023/0044A patent/JOP20230044A1/ar unknown
- 2023-03-14 CL CL2023000728A patent/CL2023000728A1/es unknown
- 2023-03-16 DO DO2023000055A patent/DOP2023000055A/es unknown
- 2023-04-14 EC ECSENADI202327092A patent/ECSP23027092A/es unknown
- 2023-04-14 CO CONC2023/0004646A patent/CO2023004646A2/es unknown
-
2024
- 2024-04-29 CL CL2024001312A patent/CL2024001312A1/es unknown
-
2025
- 2025-11-05 JP JP2025186205A patent/JP2026041723A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA61557B1 (fr) | Composés et compositions servant d'inhibiteurs de sppl2a | |
| MA48772B1 (fr) | Inhibiteurs de kras g12c et leurs procédés d'utilisation | |
| MA62912A1 (fr) | Inhibition de la protéase 1 spécifique de l'ubiquitine (usp1) | |
| TNSN04159A1 (fr) | Synthese controlee de ziprasidone et compositions en contenant | |
| TNSN99001A1 (fr) | Indoles 2,3-substitues servant d'agents anti-inflammatoires et analgesiques | |
| MA44851A (fr) | Dérivés pyridinyltriazole substitués par des groupements amides et leurs utilisations | |
| MA40893A (fr) | Dérivés de phényltriazole à substitution hydroxyalkyle et utilisations associées | |
| MA29160B1 (fr) | Derives de triazole substitues, servant d'antagonistes d'ocytocine | |
| MA31963B1 (fr) | Composes antagonistes du recepteur du glucagon, compositions contenant de tels composes et procedes d'utilisation | |
| EA200501805A1 (ru) | Фармацевтическая композиция, содержащая ингибитор фермента дипептидилпептидазы | |
| TNSN99172A1 (fr) | 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinoleines, procede pour leur preparation et compositions pharmaceutiques les contenant | |
| TNSN98182A1 (fr) | Agonistes de prostaglandines nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant | |
| MA51204B1 (fr) | Formes pharmaceutiques comprenant un inhibiteur de la kallicréine plasmatique | |
| EP1073465A4 (en) | T-CELL INHIBITING RECEPTOR COMPOSITIONS AND THEIR USE | |
| TNSN08196A1 (fr) | Derives de pyrazine | |
| TNSN06210A1 (fr) | Nitro-oxydérivés de prostaglandines | |
| TN2009000204A1 (fr) | Spirocetones servant d'inhibiteurs d'acetyl-coa-carboxylase | |
| TNSN06051A1 (fr) | Derives de piperazine pour le traitement d'infections par le hiv | |
| TN2009000033A1 (fr) | Derives de pyrazole servant d'inhibiteurs du cytochrome p450 | |
| TNSN02015A1 (fr) | Composes nouveaux antagonistes de ppar, et compositions les contenant | |
| TNSN98140A1 (fr) | Derives d'indole inhibiteurs de cyclo-oxygenase, procede pour leur preparation et compositions pharmaceutiques les contenant | |
| MA40814A1 (fr) | Compositions pharmaceutiques pour thérapie combinée | |
| DE69837324D1 (de) | Behandlung der multiplen sklerose durch einnahme von copolymer-1 | |
| MA29791B1 (fr) | Composes therapeutiques. | |
| MA54975B1 (fr) | Anticorps anti-pcrv qui se lient à pcrv, compositions comprenant des anticorps anti-pcrv, et leurs méthodes d'utilisation |